Evidence map›Paper›PMID 42162222›Full record

ArticleCommunications medicine2026

Genotype-specific digital twins for arrhythmia ablation targeting in arrhythmogenic right ventricular cardiomyopathy.

Yingnan Zhang, Adityo Prakosa, Kelly Zhang, Richard Carrick, Jonathan Chrispin, Stefan L Zimmerman, Konstantinos Aronis, Eugene G Kholmovski, Crystal Tichnell, Brittney Murray and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Communications medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors.

Yingnan ZhangDepartment of Biomedical Engineering, Johns Hopkins University, Baltimore, MD, USA.ORCID http://orcid.org/0000-0002-2070-6786
Adityo PrakosaDepartment of Biomedical Engineering, Johns Hopkins University, Baltimore, MD, USA.ORCID http://orcid.org/0000-0002-1590-0322
Kelly ZhangDepartment of Biomedical Engineering, Johns Hopkins University, Baltimore, MD, USA.
Richard CarrickDivision of Cardiology, Department of Medicine, Johns Hopkins Hospital, Baltimore, MD, USA.
Jonathan ChrispinDivision of Cardiology, Department of Medicine, Johns Hopkins Hospital, Baltimore, MD, USA.
Stefan L ZimmermanDepartment of Radiology and Radiological Science, Johns Hopkins Hospital, Baltimore, MD, USA.ORCID http://orcid.org/0000-0002-9422-6742
Konstantinos AronisDivision of Cardiology, Department of Medicine, Johns Hopkins Hospital, Baltimore, MD, USA.ORCID http://orcid.org/0000-0001-7189-8434
Eugene G KholmovskiAlliance for Cardiovascular Diagnostic and Treatment Innovation, Johns Hopkins University, Baltimore, MD, USA.ORCID http://orcid.org/0000-0002-3271-7247
Crystal TichnellDivision of Cardiology, Department of Medicine, Johns Hopkins Hospital, Baltimore, MD, USA.
Brittney MurrayDivision of Cardiology, Department of Medicine, Johns Hopkins Hospital, Baltimore, MD, USA.
Cynthia JamesDivision of Cardiology, Department of Medicine, Johns Hopkins Hospital, Baltimore, MD, USA.ORCID http://orcid.org/0000-0001-8040-4600
Hugh CalkinsDivision of Cardiology, Department of Medicine, Johns Hopkins Hospital, Baltimore, MD, USA.
Natalia A TrayanovaDepartment of Biomedical Engineering, Johns Hopkins University, Baltimore, MD, USA. ntrayanova@jhu.edu.ORCID http://orcid.org/0000-0002-8661-063X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundArrhythmogenic Right Ventricular Cardiomyopathy (ARVC) is a severe genetic heart disease that predominantly affects young athletic individuals and carries a high risk of ventricular tachycardia (VT) and sudden cardiac death. Catheter-based radiofrequency ablation is the state-of-the-art treatment for VT; however, its effectiveness in ARVC is limited by high recurrence rates. This study aims to develop a personalized approach to improve ablation outcomes in ARVC.

methodsWe developed a non-invasive digital twin-based framework, termed GenDIRECT, that simulates cardiac electrical activity on patient-specific heart models to predict the optimal VT ablation targets. This retrospective study included 30 patients with ARVC of two common ARVC genotypes (GE and PKP2). Among them, 25 underwent a single clinical ablation, and 5 had repeat ablation within 12 months of the initial ablation. Predicted targets were compared with clinically delivered ablation lesions in patients who underwent initial and/or repeat procedures.

resultsHere, we show that GenDIRECT-predicted ablation targets closely align with clinical ablation lesions (Dice score = 89.47%) in patients with successful initial procedures (n = 25) and are associated with significantly smaller lesion volumes (p = 5.39*10

conclusionsGenDIRECT has the potential to guide clinical VT ablation procedures in ARVC by identifying comprehensive patient-specific targets. This approach may improve procedural efficacy, reduce arrhythmia recurrence, and decrease the need for repeat ablation and subsequent hospitalizations.

Identifiers

PMID42162222
PMCPMC13462719

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.